Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 10/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30259053 | 0.98 | MAOB (0.50) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| Formic Acid SCHEMBL31105273 | 0.94 | MAOB (0.47) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| Trifluoroacetic Acid SCHEMBL29651920 | 0.89 | MCHR1 (0.49) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL173528 | 0.84 | MAOB (0.52) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL27979408 | 0.83 | KEAP1 (0.56) | MAOBKEAP1NAMPTHDAC1CYP2C9 | |
| Hydrochloric Acid SCHEMBL15232009 | 0.82 | MAOB (0.51) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL15038280 | 0.82 | MAOB (0.55) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL4402398 | 0.82 | KEAP1 (0.50) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL12327197 | 0.82 | MAOB (0.51) | MAOBKEAP1MEN1CYP1A2KMT2A | |
| SCHEMBL3492329 | 0.81 | MAOB (0.58) | MAOBKEAP1NAMPTMCHR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728234-B1 | RADIOLABELED COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2025-05-14 | — | — | EP | claimed |
| EP-3856735-B1 | FUSED BICYCLIC HETEROCYCLES AS THERAPEUTIC AGENTS | UNIV NEW YORK (US) | 2023-09-06 | — | — | EP | claimed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | claimed |
| EP-3172205-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2017-05-31 | — | — | EP | claimed |
| WO-2016012958-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-01-28 | — | — | WO | claimed |
| WO-2014111871-A1 | 4,5-DIHYDROISOXAZOLE DERIVATIVES AS NAMPT INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| WO-2002060440-A1 | NOVEL FORMS OF 2,3-DIMETHYL-8-(2-ETHYL-6-METHYLBENZYLAMINO)-IMIDAZO (1,2-A)PYRIDINE-6-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | WO | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | ACCENT THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025076501-A1 | HIGH THROUGHPUT PARALLEL SYNTHESIS OF SMALL MOLECULE DEGRADERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119095839-A | Quinoline derivatives as modulators and related products of Mas-associated G protein receptor X2 | 伊赛恩特制药公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118786117-A | Heterocyclic amides and methods of use thereof | 亚根达医疗公司 | 2024-10-15 | — | — | CN | disclosed |
| US-4962100-A | 3-Condensed imidazolium-cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-10-09 | — | — | US | disclosed |
| US-4864022-A | 3-Condensed imidazolium-cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| US-4788185-A | Cephalosporin compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-11-29 | — | — | US | disclosed |
| EP-0203271-A2 | Antibacterial compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1986-12-03 | — | — | EP | disclosed |
| WO-1986005183-A1 | ANTIBACTERIAL COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1986-09-12 | — | — | WO | disclosed |
| EP-0160252-A2 | Antibacterial compounds | Takeda Chemical Industries, Ltd. (JP) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179013-A1 | INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF | DHX9, DHX29, DDX39B | MAOB 3798/4885KEAP1 657/4885MEN1 3047/4885 |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | MAOB 105/4885KEAP1 278/4885MEN1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.